| 000 | 01203 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250513095721.0 | ||
| 264 | 0 | _c19961004 | |
| 008 | 199610s 0 0 eng d | ||
| 022 | _a0027-8874 | ||
| 024 | 7 |
_a10.1093/jnci/88.17.1175 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJohnson, D H | |
| 245 | 0 | 0 |
_aCombined-modality therapy for unresectable, stage III non-small-cell lung cancer--caveat emptor or caveat venditor? _h[electronic resource] |
| 260 |
_bJournal of the National Cancer Institute _cSep 1996 |
||
| 300 |
_a1175-7 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Editorial | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Small Cell _xdrug therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aRadiotherapy Dosage |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tJournal of the National Cancer Institute _gvol. 88 _gno. 17 _gp. 1175-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/jnci/88.17.1175 _zAvailable from publisher's website |
| 999 |
_c8777374 _d8777374 |
||